BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...2020 by Mei Mei Hu, Lou ReeseUniversity collaborators: University of Nebraska...
BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

...of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). The study, which is being conducted at the University of Nebraska...
BioCentury | Sep 5, 2019
Preclinical News

2016 study on gut integrin HIV target can't be replicated

...α4β7 mAb treatment was halted in 18 monkeys infected with SIV. Byrareddy is now a University of Nebraska...
BioCentury | Jul 18, 2019
Translation in Brief

What Excision needs to demonstrate before bringing CRISPR-HIV therapy to clinic

...before it should be tested in humans. In a Nature Communications paper published July 2, University of Nebraska...
...CRISPR-mediated off-target effects in the mice. Elizabeth S. Eaton, Staff Writer Excision BioTherapeutics Inc. National Institutes of Health Temple University University of Nebraska...
BioCentury | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

...e-mail: kamel.khalili@temple.edu CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. e-mail: hegendel@unmc.edu Elizabeth S. Eaton ART CRISPR HIV Kamel Khalili Temple University University of Nebraska...
BioCentury | Apr 27, 2018
Company News

Taconic gains rights to Easi-CRISPR tech

...technology to generate rodent models. University of Nebraska, Lincoln, Neb. Taconic Biosciences, Rensselaer, N.Y. Business: Cancer Shannon Lehnbeuter Taconic Biosciences University of Nebraska...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...Breast cancer Cell-based; mouse; patient sample Inhibiting EHD2 could help treat triple-negative breast cancer (TNBC). University of Nebraska...
...PAF1) Prostate cancer Cell-based Inhibiting PAF1 could restore sensitivity to docetaxel in resistant prostate cancers. University of Nebraska...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Infectious disease

...online Feb. 6, 2018 doi:10.1038/s41467-018-02885-x CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. email: hegendel@unmc.edu Hongjiang Li Tivicay University of Nebraska...
BioCentury | Feb 3, 2017
Company News

Ritter, University of Nebraska deal

...Ritter Pharmaceuticals Inc. (NASDAQ:RTTR), Los Angeles, Calif. University of Nebraska , Lincoln, Neb. Business: Endocrine/Metabolic Alicia Parker RP-G28 Ritter Pharmaceuticals Inc. University of Nebraska...
BioCentury | Jan 12, 2017
Clinical News

TGR-1202: Ph IIa started

...TG Therapeutics said the University of Nebraska Medical Center began an open-label, U.S. Phase IIa trial to evaluate...
Items per page:
1 - 10 of 59
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...2020 by Mei Mei Hu, Lou ReeseUniversity collaborators: University of Nebraska...
BioCentury | Feb 26, 2020
Product Development

U.S. testing of coronavirus vaccine, therapeutic begin

...of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). The study, which is being conducted at the University of Nebraska...
BioCentury | Sep 5, 2019
Preclinical News

2016 study on gut integrin HIV target can't be replicated

...α4β7 mAb treatment was halted in 18 monkeys infected with SIV. Byrareddy is now a University of Nebraska...
BioCentury | Jul 18, 2019
Translation in Brief

What Excision needs to demonstrate before bringing CRISPR-HIV therapy to clinic

...before it should be tested in humans. In a Nature Communications paper published July 2, University of Nebraska...
...CRISPR-mediated off-target effects in the mice. Elizabeth S. Eaton, Staff Writer Excision BioTherapeutics Inc. National Institutes of Health Temple University University of Nebraska...
BioCentury | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

...e-mail: kamel.khalili@temple.edu CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. e-mail: hegendel@unmc.edu Elizabeth S. Eaton ART CRISPR HIV Kamel Khalili Temple University University of Nebraska...
BioCentury | Apr 27, 2018
Company News

Taconic gains rights to Easi-CRISPR tech

...technology to generate rodent models. University of Nebraska, Lincoln, Neb. Taconic Biosciences, Rensselaer, N.Y. Business: Cancer Shannon Lehnbeuter Taconic Biosciences University of Nebraska...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...Breast cancer Cell-based; mouse; patient sample Inhibiting EHD2 could help treat triple-negative breast cancer (TNBC). University of Nebraska...
...PAF1) Prostate cancer Cell-based Inhibiting PAF1 could restore sensitivity to docetaxel in resistant prostate cancers. University of Nebraska...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Infectious disease

...online Feb. 6, 2018 doi:10.1038/s41467-018-02885-x CONTACT: Howard Gendelman, University of Nebraska Medical Center, Omaha, Neb. email: hegendel@unmc.edu Hongjiang Li Tivicay University of Nebraska...
BioCentury | Feb 3, 2017
Company News

Ritter, University of Nebraska deal

...Ritter Pharmaceuticals Inc. (NASDAQ:RTTR), Los Angeles, Calif. University of Nebraska , Lincoln, Neb. Business: Endocrine/Metabolic Alicia Parker RP-G28 Ritter Pharmaceuticals Inc. University of Nebraska...
BioCentury | Jan 12, 2017
Clinical News

TGR-1202: Ph IIa started

...TG Therapeutics said the University of Nebraska Medical Center began an open-label, U.S. Phase IIa trial to evaluate...
Items per page:
1 - 10 of 59